Analyst Price Target is $13.00
▲ +450.85% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for AC Immune in the last 3 months. The average price target is $13.00, with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 450.85% upside from the last price of $2.36.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in AC Immune. This Buy consensus rating has held steady for over two years.
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.